Iradimed (NASDAQ:IRMD) Updates FY 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.710-1.810 for the period, compared to the consensus estimate of 1.750. The company issued revenue guidance of $78.0 million-$82.0 million, compared to the consensus revenue estimate of $80.7 million. Iradimed also updated its Q1 2025 guidance to 0.390-0.430 EPS.

Iradimed Price Performance

Shares of Iradimed stock traded down $4.58 during trading on Thursday, hitting $55.90. 69,002 shares of the stock were exchanged, compared to its average volume of 40,757. The stock has a market cap of $708.25 million, a price-to-earnings ratio of 38.33 and a beta of 0.82. The firm’s 50-day moving average price is $57.16 and its 200 day moving average price is $52.02. Iradimed has a 12-month low of $40.18 and a 12-month high of $63.29.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings data on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.05). Iradimed had a return on equity of 23.99% and a net margin of 26.12%. As a group, research analysts forecast that Iradimed will post 1.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Iradimed from a “strong-buy” rating to a “buy” rating in a research note on Thursday.

Insider Buying and Selling

In other news, CFO John Glenn sold 2,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares in the company, valued at $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 37.10% of the stock is owned by company insiders.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.